4-chloro-2-methyl-8-quinolinesulfonyl chloride | 1121527-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-chloro-2-methyl-8-quinolinesulfonyl chloride
• 英文别名: 4-chloro-2-methylquinoline-8-sulfonyl chloride
• CAS: 1121527-69-2
• 化学式: C₁₀H₇Cl₂NO₂S
• 分子量: 276.143
• InChiKey: GYHCPIZEUGCWNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  55.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-2-methyl-8-quinolinesulfonyl chloride 在 氨 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以82%的产率得到4-chloro-2-methyl-8-quinolinesulfonamide
  参考文献：
  名称：

  Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38

  摘要：

  Starting from the micromolar 8-quinoline carboxamide high-throughput screening hit la, a systematic exploration of the structure activity relationships (SAR) of the 4-, 6-, and 8-substituents of the quinoline ring resulted in the identification of approximately 10-100-fold more potent human CD38 inhibitors. Several of these molecules also exhibited pharmacokinetic parameters suitable for in vivo animal studies, including low clearances and decent oral bioavailability. Two of these CD38 inhibitors, 1ah and 1ai, were shown to elevate NAB tissue levels in liver and muscle in a diet-induced obese (DIO) C57BL/6 mouse model. These inhibitor tool compounds will enable further biological studies of the CD38 enzyme as well as the investigation of the therapeutic implications of NAD enhancement in disease models of abnormally low NAD.

  DOI：

  10.1021/acs.jmedchem.5b00992
• 作为产物：
  描述：

  4-氯喹哪啶 在 氯磺酸 作用下， 反应 18.0h， 以11%的产率得到4-chloro-2-methyl-8-quinolinesulfonyl chloride
  参考文献：
  名称：

  [EN] 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE
  [FR] 4-BENZYLAMINOQUINOLÉINES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION EN THÉRAPIE

  摘要：

  公开号：

  WO2009024611A3

文献信息

• 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
  申请人：Amberg Wilhelm

  公开号：US20100222346A1

  公开（公告）日：2010-09-02

  The present invention relates to 4-benzylaminoquinolines of the formula (I) or physiologically tolerated salts thereof. The invention relates to pharmaceutical compositions comprising such quinolines, and the use of such quinolines for therapeutic purposes. The quinolines are GIyTI inhibitors.

  本发明涉及式（I）的4-苄氨基喹啉或其生理上可耐受的盐。本发明涉及包含这种喹啉的药物组合物，以及使用这种喹啉进行治疗目的的方法。这些喹啉是GIyTI抑制剂。
• 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
  申请人：Amberg Wilhelm

  公开号：US08420670B2

  公开（公告）日：2013-04-16

  The present invention relates to 4-benzylaminoquinolines of the formula (I) or physiologically tolerated salts thereof. The invention relates to pharmaceutical compositions comprising such quinolines, and the use of such quinolines for therapeutic purposes. The quinolines are GIyTI inhibitors.

  本发明涉及式(I)的4-苄基氨基喹啉或其生理上可耐受的盐。本发明涉及包含这样的喹啉的药物组合物，以及使用这样的喹啉进行治疗目的。这些喹啉是GIyTI抑制剂。
• 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE
  申请人：Abbott GmbH & Co. KG

  公开号：EP2178842A2

  公开（公告）日：2010-04-28
• US8420670B2
  申请人：——

  公开号：US8420670B2

  公开（公告）日：2013-04-16
• [EN] 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY<br/>[FR] 4-BENZYLAMINOQUINOLÉINES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION EN THÉRAPIE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2009024611A2

  公开（公告）日：2009-02-26

  The present invention relates to 4-benzylaminoquinolines of the formula (I) or physiologically tolerated salts thereof. The invention relates to pharmaceutical compositions comprising such quinolines, and the use of such quinolines for therapeutic purposes. The quinolines are GIyTI inhibitors.